Twist Bioscience Corp
Company Profile
Business description
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company’s proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Contact
681 Gateway Boulevard
South San FranciscoCA94080
USAT: +1 800 719-0671
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 September 2026
Employees
979
Stocks News & Analysis
stocks
ASX healthcare share undervalued post earnings
stocks
ASX energy share sees 363% increase in dividend
stocks
Wide moat share remains cheap despite rising costs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,388.60 | 4.70 | -0.05% |
| CAC 40 | 8,439.20 | 13.81 | -0.16% |
| DAX 40 | 26,266.14 | 159.54 | 0.61% |
| Dow JONES (US) | 53,577.40 | 160.24 | 0.30% |
| FTSE 100 | 10,886.16 | 31.84 | 0.29% |
| HKSE | 25,511.10 | 6.23 | -0.02% |
| NASDAQ | 26,151.30 | 171.11 | 0.66% |
| Nikkei 225 | 65,580.17 | 276.26 | -0.42% |
| NZX 50 Index | 14,005.47 | 12.75 | 0.09% |
| S&P 500 | 7,677.28 | 24.42 | 0.32% |
| S&P/ASX 200 | 9,179.10 | 4.60 | -0.05% |
| SSE Composite Index | 3,889.44 | 7.44 | 0.19% |